# Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

> **NCT04911127** · PHASE1 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 67 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Cannabis

## Interventions

- **DRUG:** 200mg Cannabidiol by capsules twice daily
- **DRUG:** 400mg Cannabidiol by capsules twice daily
- **DRUG:** Placebo capsules

## Key facts

- **NCT ID:** NCT04911127
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911127, "Therapeutic Response of Cannabidiol in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04911127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*